Assessment of sarcopenic state in liver diseases and treatment efficacy by carnitine supplementatio
Not Applicable
- Conditions
- sarcopenia in liver diseases
- Registration Number
- JPRN-UMIN000030589
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences
- Brief Summary
o case was admitted.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 30
Inclusion Criteria
Not provided
Exclusion Criteria
1)The patient who has already taken carnitine 2)The patient equivalent to stageIV in hepatocellular carcinoma 3)The pregnant woman 4)The breast-feeding women 5)The patient who received other study medicine or the clinical experimental medicine within three months before dosage start of the study 6)In addition, the patient whom principal investigators judged to be inappropriate as a study subject
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Prevalence of sarcopenia in liver diseases, Treatment efficacy by carnitine supplementation(after 3months, after 6months)
- Secondary Outcome Measures
Name Time Method serum ammonia neuropsychiatric function test